Qiagen (NYSE:QGEN – Get Free Report) is projected to issue its quarterly earnings data after the market closes on Wednesday, February 5th. Analysts expect the company to announce earnings of $0.60 per share and revenue of $518.54 million for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link.
Qiagen Stock Up 0.3 %
Shares of QGEN stock opened at $44.66 on Monday. The company has a current ratio of 2.17, a quick ratio of 1.89 and a debt-to-equity ratio of 0.39. Qiagen has a 12 month low of $40.15 and a 12 month high of $49.30. The stock has a market cap of $9.91 billion, a P/E ratio of 111.32, a P/E/G ratio of 3.03 and a beta of 0.37. The company has a 50 day simple moving average of $43.72 and a two-hundred day simple moving average of $43.21.
Wall Street Analyst Weigh In
A number of equities analysts recently commented on the company. HSBC cut Qiagen from a “buy” rating to a “hold” rating and set a $47.64 target price on the stock. in a report on Thursday, October 17th. Jefferies Financial Group reaffirmed a “buy” rating and set a $52.50 price objective (up from $40.83) on shares of Qiagen in a research report on Tuesday, December 10th. Hsbc Global Res upgraded Qiagen to a “hold” rating in a research note on Thursday, October 17th. Finally, Morgan Stanley restated an “equal weight” rating and set a $46.67 target price (down previously from $48.61) on shares of Qiagen in a research note on Monday, January 6th. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $50.07.
About Qiagen
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.
See Also
- Five stocks we like better than Qiagen
- What Makes a Stock a Good Dividend Stock?
- 3 Stocks to Gain From Trump’s Return-to-Office Mandate
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Crane Stock Soars, But the Best Could Be Yet to Come: Here’s Why
- Stock Dividend Cuts Happen Are You Ready?
- ServiceNow Stock Slips, But AI Expansion Signals Long-Term Gains
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.
